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Abstract. – Background and Objectives:
Molecular epidemiology of hepatitis C virus
(HCV) is very important for the treatment of he-
patitis C infection. The aim of this study was to
determine the distribution of HCV genotypes in
Bushehr province (South West of Iran).
Materials and Methods: A total of 100 pa-
tients who were detected as positive for HCV an-
tibody (by using ELISA method and RIBA test)
referred to Arya Virology Laboratory between
2007-2009 in order to molecular diagnosis and
furthermore virus genotyping. After detection of
HCV, RNA genotyping of virus was done by us-
ing genotype specific primers.
Results: Genotype 1a was found in 49% of
the patients and genotype 3a was found in 40%
of the patients and 1b in 5% of patients, while
the genotype of the virus could not be identi-
fied in 5% of the patients. Finally, in 1% of pa-
tients coinfection due to 1a-3a genotypes was
identified. 
Conclusion: The dominant genotype of HCV
in Bushehr province, Iran, was determined as 1a.
Key Words:
Hepatitis C virus, Genotyping, RT-PCR, Bushehr,
Iran.
Introduction
Hepatis C virus (HCV) is an enveloped, sin-
gle-stranded RNA virus, a member of the  Fla-
viviridae family and genus hepacivirus1,2. HCV is
a causative agent for chronic, acute and fulmi-
nant hepatitis3,4. About 75 percent of patients
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with acute hepatitis C ultimately develop chronic
infection1. Only a minority of cases of acute
HCV recover completely, with spontaneous virus
eradication. In most cases the acute infection
progresses to chronicity. Chronic HCV infection
is defined as an infection that persists for more
than 6 months, with or without clinical manifes-
tations of hepatic or extrahepatic disease. Chron-
ic type of this infection can cause cirrhosis, liver
failure, and liver cancer. HCV infection is a glob-
al health problem and it is estimated that 200
million people of the world population are infect-
ed5. The global spread of chronic HCV infection
coincided with the widespread use of transfused
blood and blood products and with the expansion
of intravenous drug use but decreased prior to the
wide implementation of anti-HCV screening6.
There are at least six major genotypes designated
by Arabic numerals and more than 50 subtypes
of HCV identified by lower case letters. The dif-
ferent genotypes have different geographic distri-
butions1,4. Genotype determination of HCV is
one of the most important factors in order to pre-
diction of the viral persistency, pathogenicity and
resistancy to antivirals7. The success and the
treatment period of interferon and ribavirin
seems to be related to the genotype of virus8.
Furthermore, HCV genotyping is a useful tool to
determine its molecular epidemiology, as they
are indicative of transmission route of infec-
tion9,10. There is no published data about the dis-
tribution of HCV genotypes from Bushehr
province (South West of Iran). Prevalence of
HCV genotypes in Bushehr is an issue that is not
sufficiently investigated and there is a need,
therefore, to study this in detail.
2010; 14: 861-864
K. Vahdat, H. Keyvani, S.M. Tabib, S. Rostamabadi, S.M. Valizadeh, S. Cheraghi, S. Shamsian, K. Zandi
Results
Out of 100 patients, 96 (96%) were males and
4 (4%) were females. All patients were positive
for the presence of HCV RNA in their sera. The
results of HCV genotyping by using primer
based method showed that 49 samples (49%)
were 1a, 40 (40%) were identified as 3a, 5 (5%)
were detected as 1b, while the genotype of five
samples(5%) didn’t reveal in our study. Also, one
patient (1%) was infected by two genotypes (1a
and 3a) simultaneously. 
Discussion
Epidemiological studies in different regions
of the world show the differences in distribution
of HCV genotypes. The geographical distribu-
tion of HCV genotypes is important for the epi-
demiological studies in terms of distribution
and possible risk groups13. Also, HCV genotype
determination is an important need for clini-
cians in order to decide about the duration of
antiviral treatment14. In this context, the goal of
our study was to identify the prevalence of HCV
genotypes in Bushehr, Iran. Based on results, 49
patients (49%) were infected by 1a genotype, 40
patients (40%) showed the infection with geno-
type 3a, 5 patients (5%) were infected by 1b
and 1 patient (1%) was coinfected by two geno-
types simultaneously (1an and 3a). Meanwhile
the genotype of 5 patients (5%) didn’t identify.
Our results are nearly similar to those studies
which have already been conducted by different
investigators in Tehran, Iran15,16. Our investiga-
tion confirmed that the dominant genotype in
Bushehr province is 1a which is in accordance
to other reports from the different area of
Iran9,15,16. Regarding the scientific reports, the
prevalence of chronic HCV infection in patients
with liver diseases (chronic hepatitis, cirrhosis
and hepatocellular carcinoma) is very high in
southern Europe and Japan (60-90%), interme-
diate in other part of Europe, the United States,
Australia and Africa (30-60%) and lower in
China and other countries of the Far East (10-
30%)17,18. The prevalence of chronic HCV carri-
ers varies greatly far depending on geographical
location and the characteristics of the popula-
tion analysed. Low rates are found in the gener-
al adult population in North America and West-
ern Europe, the Middle East and South Ameri-
Materials and Methods
This research was approved by the Ethical Com-
mittee of Bushehr University of Medical Sciences.
The sera were collected from 100 patients referred
to the Arya Virology Laboratory from 2007 to
2009. The mean age of patients was 27.8 y.o.
Serolgocical Assay
The sera were collected from 100 patients. All
sera were initially tested for anti-HCV antibody
by Enzyme Linked Immuno Sorbent Assay
(ELISA) test (Ortho; HCV 3.0 ELISA Test Sys-
tem; Ortho-Clinical Diagnostics, Raritan, NJ,
USA). For positive sera by ELISA, the confirma-
tory Recombinant Immunoblot Assay (RIBA) test
(Deciscan HCV plus; Sanofi Diagnostics Pasteur,
SA Marnes la Coquuette, France) was carried out3.
The sera which were detected as positive for
HCV antibody aliquoted and stored immediately
at –70°C for further studies.
Extraction of Hepatitis C Virus RNA and
cDNA Synthesis
In this study, RNA extraction kit (QIAGEN)
was used in roder to HCV RNA extraction from
the sera of patients. Extracted HCV-RNA was re-
verse transcribed into cDNA by using random
primers (Sensicript RT kit; QIAGEN, Poison In-
formation Centre Mainz, Germany)11.
Hepatitis C Virus-RNA Detection
Synthesized cDNA was amplified by using
nested-PCR which directed at the 5’ untranslated
region. Two sets of primers were synthesized
(ROCHE; Roche Diagnostics GmbH, Roche Ap-
plied Science, Mannheim, Germany) which the
first set 5`-AGC GTC TAG CCA TGG CGT -3`,
called forward external primer, and 5`- GCA
CGG TCT ACG AGA CCT-3`, named reverse
external primer. The second set 5`-GTG GTC
TGC GGA ACC GG-3`, called forward inner
primer, and 5`- GGG CAC TCG CAA GCA
CCC-3`, named reverse inner primer of 5’UTR
region of HCV genome. The RT-PCR was per-
formed as described previously9.
Genotyping
Viral RNA which was extracted from the sera
by using RNA extraction kit(QIAGEN) was im-
mediately reverse transcribed to the cDNA as
mentioned above. HCV genotyping was carried
out by using primer based genotyping method as
described previously12.
862
ca. The number of infected individuals is partic-
ularly high in Egypt, in the elderly population
in some Mediterranean areas, including south-
ern Italy19. HCV prevalence in general popula-
tion is less than one percent in Iran20. Higher
rates have been reported in South East Asian
countries, including India (1.5%), Malaysia
(2.3%), and the Philippines (2.3%)5. HCV geno-
type 1a is prevalent in blood donors from Mexi-
co21. HCV genotype 1b is dominant in the
northeastern Bosnia and Herzegovina and In-
donesia and Turkey13,22,23. HCV genotype 3a is
the most predominant genotype in Pakistan and
Thailan24-26. Also, in one study which was con-
ducted in Pakistan, showed that there is a strong
association between chronic HCV infection and
hepatocellular carcinoma24. HCV genotype de-
termination is important when treatment is be-
ing considered, since some genotypes respond
more favorably to the medications. Also HCV
genotyping could determine the length of thera-
py, e.g., treatment for genotypes 2 and 3 re-
quires only 24 weeks while genotypes 1 and 4
require 48 weeks7. Also, the results of this study
have some similarities with other studies in Pak-
istan and India, which showed that genotype 3
is very prevalent and genotype 2 is very rare10,27.
Although high prevalence of 49% HCV 1a
genotype and low prevalence of 5% 1b HCV
genotype were observed among patients in
Bushehr province, Iran.
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